Lexicon director buys 2,000 LXRX shares at $1.49

LEXICON PHARMACEUTICALS director Raymond Debbane reported an open-market purchase of company stock.

Rhea-AI Filing Summary

LEXICON PHARMACEUTICALS director Raymond Debbane reported an open-market purchase of company stock. He bought 2,000 shares of common stock at a price of $1.49 per share, bringing his directly held stake to 1,906,186 shares.

The filing also lists indirect holdings in Lexicon Pharmaceuticals common stock through various affiliated investment entities, including 1,538,462 shares held by Avicenna Life Sci Master Fund LP and related parties, 7,362,368 shares by Invus Public Equities, L.P. and related parties, 5,451,204 shares by Invus US Partners, LLC and related parties, and 35,402,689 shares by Invus, L.P. and related parties.

Insider Trade Summary

Net Buyer: 2,000 shares

Net Buy 5 txns

Insider DEBBANE RAYMOND

Role Director

Bought 2,000 shs ($3K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	2,000	$1.49	$3K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 1,906,186 shares (Direct); Common Stock — 1,538,462 shares (Indirect, By Avicenna Life Sci Master Fund LP and related parties); Common Stock — 7,362,368 shares (Indirect, By Invus Public Equities, L.P. and related parties); Common Stock — 5,451,204 shares (Indirect, By Invus US Partners, LLC and related parties); Common Stock — 35,402,689 shares (Indirect, By Invus, L.P. and related parties)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Raymond Debbane report in this Form 4 for LEXICON PHARMACEUTICALS (LXRX)?

Raymond Debbane reported buying 2,000 shares of Lexicon Pharmaceuticals common stock. The shares were acquired in an open-market purchase at a price of $1.49 per share, and increased his directly held position to 1,906,186 shares.

At what price did the LXRX director buy shares in this Form 4 filing?

The director bought Lexicon Pharmaceuticals common stock at $1.49 per share. This open-market purchase covered 2,000 shares, modestly increasing his direct ownership while also accompanying disclosure of large indirect holdings through affiliated investment entities.

How many LXRX shares does Raymond Debbane directly own after this reported transaction?

After the reported transaction, Raymond Debbane directly owns 1,906,186 shares of Lexicon Pharmaceuticals common stock. This total reflects the addition of 2,000 shares acquired in the open market at $1.49 per share on the reported transaction date.

What indirect LXRX holdings associated with Raymond Debbane are disclosed in this Form 4?

Indirect holdings include 1,538,462 shares via Avicenna Life Sci Master Fund LP, 7,362,368 via Invus Public Equities, L.P., 5,451,204 via Invus US Partners, LLC, and 35,402,689 via Invus, L.P., reflecting substantial positions through affiliated investment entities.

Does this LXRX Form 4 show any stock sales by Raymond Debbane or related entities?

The Form 4 shows no stock sales; it reports an open-market purchase of 2,000 Lexicon Pharmaceuticals shares. The remaining entries reflect reported indirect holdings through various investment entities rather than additional buy or sell transactions during the reported period.

What is the net share change reported for Raymond Debbane in this LXRX Form 4?

The net share change is a purchase of 2,000 Lexicon Pharmaceuticals shares. This net-buy result comes solely from one open-market transaction, with no reported sales, raising his direct holdings to 1,906,186 shares of common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/27/2026 - 08:33 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DEBBANE RAYMOND

(Last) (First) (Middle)

2445 TECHNOLOGY FOREST BLVD.

11TH FLOOR

(Street)

THE WOODLANDS TX 77381

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEXICON PHARMACEUTICALS, INC. [ LXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/25/2026		P		2,000	A	$1.49	1,906,186	D
Common Stock								1,538,462	I	By Avicenna Life Sci Master Fund LP and related parties
Common Stock								7,362,368	I	By Invus Public Equities, L.P. and related parties
Common Stock								5,451,204	I	By Invus US Partners, LLC and related parties
Common Stock								35,402,689	I	By Invus, L.P. and related parties

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Raymond Debbane	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.